What is the damage? Testicular germ cell tumour survivors deficient in testosterone at risk of metabolic syndrome and a need for medical intervention

• Published in: Medical oncology (Northwood, London, England) Vol. 37; no. 9; p. 82
• Main Authors: Poniatowska, Grazyna, Michalski, Wojciech, Kucharz, Jakub, Jonska-Gmyrek, Joanna, Wieszczy, Paulina, Nietupski, Karol, Demkow, Tomasz, Dedecjus, Marek, Sadowska, Malgorzata, Kalinowski, Tomasz, Grochulska-Nalazek, Beata, Nowatorska, Ada, Stelmasiak, Pawel, Wiechno, Pawel J.
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.09.2020; Springer Nature B.V
• Subjects: Adult; Aged; Body composition; Cancer Survivors - statistics & numerical data; Follow-Up Studies; Hematology; Humans; Internal Medicine; Male; Medicine; Medicine & Public Health; Metabolic disorders; Metabolic syndrome; Metabolic Syndrome - etiology; Middle Aged; Multivariate analysis; Neoplasm Staging; Neoplasms, Germ Cell and Embryonal - metabolism; Neoplasms, Germ Cell and Embryonal - physiopathology; Neoplasms, Germ Cell and Embryonal - therapy; Obesity - complications; Oncology; Original Paper; Pathology; Retrospective Studies; Risk Factors; Testicular cancer; Testicular Neoplasms - metabolism; Testicular Neoplasms - physiopathology; Testicular Neoplasms - therapy; Testosterone; Testosterone - deficiency; Testicular germ cell tumours; Testosterone; Metabolic syndrome; Deficiency; Hypogonadism
• ISSN: 1357-0560; 1559-131X
• DOI: 10.1007/s12032-020-01407-4

Testicular germ cell tumours (TGCT) survivors are coping with late treatment sequelae. Testosterone deficiency may contribute to earlier onset of metabolic syndrome. The study aimed to assess connections between serum testosterone concentrations and metabolic disorders as well as body composition in TGCT survivors. 336 TGCT patients with over two years of complete post-treatment remission were divided into three groups: definite testosterone deficiency (< 8 nmol/L), ‘grey zone’ (8–12 nmol/L) and normal testosterone (> 12 nmol/L; control group) to assess differences in metabolism. Univariate and multivariate analyses were performed. The multivariate analysis assessed the risk of metabolic disorders and changes in body composition with regard to testosterone concentrations adjusted for age, smoking history, clinical stage, type of treatment and follow-up period. 14% of patients presented with definite testosterone deficiency; 46% were in the ‘grey zone’. On multivariate analysis, low testosterone levels were related to hyperglycemia, hypercholesterolemia, hypertriglyceridemia, inflammatory processes, procoagulant state and obesity. The odds ratio (OR) for the onset of metabolic syndrome was 2.87 (95% CI 1.74–4.73, p  < 0.001) for the ‘grey zone’ patients and 7.92 (95% CI 3.76–16.70, p  < 0.001) for those with definite testosterone deficiency. Testosterone concentrations were independently associated with metabolic disorders in TGCT survivors. Testicular cancer survivors often have lower testosterone and metabolic disorders. Apart from recurrence, follow-up should focus on promoting a healthy lifestyle, preventing and managing late effects.